Abstract:IntroductionCirculating long noncoding RNAs (lncRNAs) are emerging as valuable biomarkers in numerous diseases. However the expression signature of circulating lncRNAs is yet to be identified in diabetic cardiomyopathy (DCM). We used computational and system biology approach to predict circulating lncRNAs using plasma RNA before and after DCM.HypothesisWe hypothesized that lncRNAs could serve as blood‐based prognostic and diagnostic biomarkers in DCM detection.MethodsThe left ventricular function was measured with echocardiography in control and db/db mice. Expression profiling of lncRNAs was performed using LncRNA Array v3.0 (8 × 60K, Arraystar).ResultsA total of 17,124 lncRNAs and 13,333 mRNAs were profiled of which 814 lncRNAs and 2707 mRNAs were deregulated, and more than half were intergenic lncRNAs and antisense lncRNAs. Ten dysregulated plasma lncRNAs were validated by quantitative PCR assays. For the gene ontologies related to plasma, the enrichment was observed for those mRNAs which were found to be significantly co‐expressed with the neighboring lncRNAs during DCM. Bioinformatics analysis revealed that the altered lncRNAs regulated the differentially expressed mRNAs which were profoundly enriched for pathways such as insulin signaling, fatty acid metabolism, MAPK signaling, and hypertrophy cardiomyopathy which in the past has been associated with diabetic pathogenesis. To evaluate the translational efficiency of our mouse model, we experimentally validated the results using human induced pluripotent cell‐derived cardiomyocytes (hiPSCs‐CMs) for the in vitro DCM model. We found that most of the gene expression patterns were repeated in hiPSCs‐CMs and several of these lncRNAs genes have been associated with DCM in the past.ConclusionCirculating lncRNAs are dysregulated in DCM, and our results depict the changing transcriptome as a function of disease progression and functional role of lncRNAs. These lncRNAs may serve as promising targets for DCM prevention, early diagnosis, and therapy.Support or Funding InformationThis work was supported, in part, by a National Institutes of Health research grant P01GM 066730 (to Dr. Bosnjak) from the United States Public Health Services, Bethesda, Maryland, USA. The funding body had no role in the design of the study, collection, analysis, and interpretation of data, and in writing the abstract.This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.

MicroRNA Expression Profiles in a Human Induced Pluripotent Stem Cell‐derived Model of Diabetic Cardiomyopathy

Expression profiles and bioinformatic analysis of microRNAs in myocardium of diabetic cardiomyopathy mice

Abstract 439: Modeling Diabetic Cardiomyopathy Model Using Human Induced Pluripotent Stem Cell-derived Cardiomyocytes

Differential Expression Profiles of Transfer RNA-Derived Small RNAs and Their Potential Roles in Diabetic Cardiomyopathy

Microarray Analysis Of Long Non-Coding Rna And Mrna Expression Profiles In Diabetic Cardiomyopathy Using Human Ipscs-Derived Cardiomyocytes.

Microarray Analysis of Long Non-Coding RNA and Mrna Expression Profiles in Diabetic Cardiomyopathy Using Human Induced Pluripotent Stem Cell–derived Cardiomyocytes

miR-340-5p Mediates Cardiomyocyte Oxidative Stress in Diabetes-Induced Cardiac Dysfunction by Targeting Mcl-1

Dihydromyricetin Prevents Diabetic Cardiomyopathy via miR-34a Suppression by Activating Autophagy

Abstract P124: Human Small Artery MicroRNA Expression Profiles: Changes in Type 2 Diabetes and Associations with Endothelial Function

Co‐expression Network Analysis of Altered Lncrnas and Mrnas in Diabetic Cardiomyopathy Using Human Ipsc‐derived Cardiomyocytes

Application of Animal Models in Diabetic Cardiomyopathy

MicroRNAs Involved in the Mitogen-Activated Protein Kinase Cascades Pathway During Glucose-Induced Cardiomyocyte Hypertrophy

Subcellular microRNAs in diabetic cardiomyopathy

Non-coding RNA-mediated endothelial-to-mesenchymal transition in human diabetic cardiomyopathy, potential regulation by DNA methylation

Human umbilical cord-derived mesenchymal stromal cells improve myocardial fibrosis and restore miRNA-133a expression in diabetic cardiomyopathy

Abstract 21261: Circulating Extracellular Vesicles From Mouse and Rat Models of Diabetes Reveal Specific Microrna Signatures as Biomarkers of Diabetic Cardiomyopathy

Analysis of differentially expressed genes related to the development of diabetic cardiomyopathy in the myocardium of type-2 diabetic rats

Disease Modeling and Phenotypic Drug Screening for Diabetic Cardiomyopathy Using Human Induced Pluripotent Stem Cells

Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Reveal Abnormal TGFβ Signaling in Type 2 Diabetes Mellitus.

Genome Wide Microarray Profiling Identified Differentially Expressed Circulating Biomarkers Associated with Early Development of Diabetic Cardiomyopathy

MicroRNAs and long non-coding RNAs in the pathophysiological processes of diabetic cardiomyopathy: emerging biomarkers and potential therapeutics